Beta-D-Glucose
|
Basic information |
| Metabolite name | Beta-D-Glucose |
 | HMDB0000516 |
 |
C00221 |
 |
64689 |
| Synonyms | β-glucose; |
| No. of studies | 16 |
|
Basic information |
| Metabolite name | Beta-D-Glucose |
| HMDB0000516 |
|
C00221 |
|
64689 |
| Synonyms | β-glucose; |
| No. of studies | 16 |
|
Relationship between Beta-D-Glucose and depression (count: 16) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M015 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M015 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M015 | Type2 | CUMS + Xiaoyaosan Bei group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M015 | Type2 | CUMS + Xiaoyaosan Nan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M051 | Type3 | fluoxetine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + low dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M066 | Type1 | CUMS vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Down |
| Study M1076 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M1076 | Type2 | depression group, post Shuganjieyu treatment vs. baseline | Plasma | Human | Down |
| Study M108 | Type2 | CUMS + BR group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M118 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M146 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M207 | Type1 | depressed group vs. control group | Faece | Kunming mouse | Up |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Down |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + low dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M591 | Type1 | LPS group vs. control group | Plasma | CD-1 mouse | Down |
| Study M592 | Type1 | CUMS group vs. control group, NMR | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + venlafaxine group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Up |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Down |